We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+18.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$151M
AUM Growth
-$29.7M
Cap. Flow
+$9.23M
Cap. Flow %
6.1%
Top 10 Hldgs %
42.62%
Holding
71
New
15
Increased
21
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$4.74M
2
IBB icon
iShares Biotechnology ETF
IBB
+$3.78M
3
GILD icon
Gilead Sciences
GILD
+$3.06M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.72M
5
MRK icon
Merck
MRK
+$2.59M

Top Sells

Rank Stock Value
1
TECH icon
Bio-Techne
TECH
+$4.35M
2
CPHD
Cepheid Inc
CPHD
+$4.07M
3
AZN icon
AstraZeneca
AZN
+$2.85M
4
BIIB icon
Biogen
BIIB
+$2.01M
5
MTD icon
Mettler-Toledo International
MTD
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Miscellaneous 14.74%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
51
Eledon Pharmaceuticals
ELDN
$270M
$541K 0.36%
+383
New +$667K
SRRA
52
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$451K 0.3%
+750
New +$507K
SIOX
53
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$340K 0.22%
2,357
-1,483
-39% -$193K
PLXP
54
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$280K 0.19%
+3,125
New +$300K
INFI
55
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$236K 0.16%
30,000
-15,300
-34% -$132K
KALV
56
DELISTED
KalVista Pharmaceuticals
KALV
$63K 0.04%
+1,250
New +$65.4K
ARWR icon
57
Arrowhead Research
ARWR
$12.5B
– –
-51,133
Closed -$295K
ASMB icon
58
Assembly Biosciences
ASMB
$709M
– –
-1,250
Closed -$143K
CRIS icon
59
Curis
CRIS
$3.64M
– –
-187
Closed -$756K
LABU icon
60
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$720M
– –
-186
Closed -$241K
TECH icon
61
Bio-Techne
TECH
$11.4B
– –
-188,000
Closed -$4.35M
TLPH icon
62
Talphera
TLPH
$63.8M
– –
-2,887
Closed -$176K
XBI icon
63
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
– –
-862,500
Closed -$53.7M
CMRX
64
DELISTED
Chimerix, Inc.
CMRX
– –
-14,152
Closed -$541K
STML
65
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-75,000
Closed -$662K
ARRY
66
DELISTED
Array Biopharma Inc
ARRY
– –
-250,000
Closed -$1.14M
CPHD
67
DELISTED
Cepheid Inc
CPHD
– –
-90,000
Closed -$4.07M
XNPT
68
DELISTED
XENOPORT, INC.
XNPT
– –
-40,000
Closed -$139K
NHLD
69
DELISTED
National Holdings Corporation
NHLD
– –
-89,530
Closed -$246K
RPRX
70
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-98,000
Closed -$494K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2015 Portfolio in Review

As of Q4 2015, Opus Point Partners Management held 71 positions worth $151M, down 16% from $181M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opus Point Partners Management deployed $9.23M of net new capital in Q4 2015, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was Loxo Oncology, Inc: 60,000 shares worth $1.71M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was AstraZeneca, an estimated $2.85M trimmed.

  • Opus Point Partners Management's largest Q4 2015 buy was Loxo Oncology, Inc: 60,000 shares worth $1.71M.
  • Opus Point Partners Management added most to Amgen in Q4 2015, an estimated $4.74M increase.
  • Opus Point Partners Management's biggest Q4 2015 reduction was AstraZeneca, cutting an estimated $2.85M.
  • Opus Point Partners Management fully exited Bio-Techne in Q4 2015, selling an estimated $4.35M.
  • Opus Point Partners Management's ten largest holdings make up 43% of its $151M portfolio in Q4 2015.
  • Opus Point Partners Management opened 15 new positions and closed 14 in Q4 2015.
  • Opus Point Partners Management's portfolio value fell 16% quarter-over-quarter to $151M.

Based on Opus Point Partners Management's 13F filing for Q4 2015, filed 16 Feb 2016.